CIGB 814

Drug Profile

CIGB 814

Alternative Names: CIGB814

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Anti-inflammatories; Antirheumatics; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Cuba (SC, Injection)
  • 31 Jan 2017 Center for Genetic Engineering and Biotechnology and Havana Ministry of Public Health, Cuba plan a phase II trial for Rheumatoid arthritis (Adjunctive treatment) in Cuba (SC) (RPCEC00000230)
  • 24 Feb 2016 CIGB has patent protection for CIGB 814 in USA, Europe, Japan and Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top